Clinical outcome | CV mortality | Non-CV mortality | ADHF |
---|
Odds ratio and 95% CI | | | |
Unadjusted | 2.57 (1.09–6.27) | 1.60 (0.17–15.5) | 1.65 (1.02–2.66) |
Model 1 | 2.12 (1.04–4.39) | 1.21 (0.33–8.96) | 1.47 (0.95–2.08) |
Model 2 | 1.62 (0.90–2.23) | 1.08 (0.41–4.29) | 1.25 (0.86–1.60) |
Model 3 | 1.04 (0.78–1.44) | 1.01 (0.43–2.63) | 1.08 (0.73–1.24) |
Model 4 | 0.70 (0.62–1.20) | 0.79 (0.36–1.82) | 0.77 (0.68–1.13) |
Model 5 | 0.68 (0.57–1.13) | 0.74 (0.35–1.76) | 0.74 (0.64–1.08) |
Model 6 | 0.42 (0.37–1.02) | 0.65 (0.40–1.61) | 0.63 (0.55–1.01) |
- Model 1: age; Model 2: model 1 plus educational attainment, and health insurance; Model 3: model 2 plus symptom onset to emergency department, and using emergency medical service to emergency department; Model 4: model 3 plus ticagrelor loading, duration since arrived at emergency department to first ECG test, duration since arrival at emergency department to first Hs-cTNT test, and duration since arrival at emergency department to Cardiologist consultation; Model 5: model 4 plus ticagrelor, statins, betablocker, renin-angiotensin-system inhibitor, and antidiabetics; Model 6: model 5 plus ST-segment elevation myocardial infarction, duration since symptom onset to undergo PCI, number of coronary arteries ≥ 70% stenosis, lesion length and location, post-PCI TIMI flow, and glycoprotein IIb/IIIa inhibitor
- CV, cardiovascular; ADHF, acute decompensated heart failure